Payers develop strategies for combination oncology drugs

11/9/2012 | Pharmalot.com

Payers are developing strategies to manage the high costs of new, combination prostate cancer drugs, such as requiring preauthorization and covering the drugs only after monotherapies have failed.

View Full Article in:

Pharmalot.com